Brief: Oncolytics Biotech granted end-of-phase 2 meeting with FDA
July 26 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics biotech to present reolysin safety data in
combination with chemotherapy at esmo 2017 congress
* Oncolytics biotech inc - has been granted an end-of-phase
2 meeting with united states food and drug administration (fda),
taking place in august 2017.
* Oncolytics biotech inc - company expects to announce
outcome of meeting with fda in q4 of 2017.
Source text for Eikon: ID:nPn6lMn1Ya
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com ;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer